Summary.-Leucocytes from normal individuals and from patients with acute myeloid leukaemia (AML) in remission receiving active immunotherapy with allogeneic AML blasts (AML-I) were cultured for 6 days with AML-I blasts, Burkitt's lymphoma cells (BL) or lymphoblastoid cells (LCL). The leucocytes were then tested for cell-mediated cytotoxicity (CMC) against 51Cr-labelled AML-I, BL or LCL target cells. There was no substantial difference in the CMC of leucocytes from patients and normals cultured without stimulation, and tested against AML-I, BL or LCL targets. Patients' leucocytes stimulated in vitro with AML-I had a greater frequency of positive CMC responses against AML-I, BL and LCL than normal individuals. The results suggest that co-cultivation of leucocytes with AML-I blasts reactivates memory cytotoxic leucocytes in AML patients receiving immunotherapy and that this test may be useful in measuring the effectiveness of immunotherapy.
WE ARE treating a number of acute myeloid leukaemia (AML) patients during remission with active immunotherapy (see Freeman et al., 1973) and without maintenance chemotherapy. The treatment protocol is based on immunotherapy trials carried out at the Royal Marsden and St Bartholomew's Hospitals (Powles et al., 1973) and entails the weekly injection of x-irradiated allogeneic (donor) AML blasts subcutaneously into 3 of the patient's limbs and BCG into the fourth. By analogy with animal leukaemias (Mathe, Pouillart and Lapeyraque, 1969; Amiel and Berardet, 1970) , the aim of active immunotherapy is to stimulate immunity to antigens on the donor leukaemic blasts in the hope that such antigens may crossreact with putative tumour-associated rejection antigens on the surface of the recipient's own (autochthonous) leukaemic blasts.
If immunotherapy is to become an acceptable form of treatment in AML and cancer in general, objective measurement of its effects are necessary. Some efforts have already been made to assess responses to immunotherapy. Thus, following autoimmunization of patients with their own leukaemic blasts the intensity of leucocyte transformation by autochthonous AML blasts increases (Powles et al., 1971 , Gutterman et al., 1973 , though to what extent this may be due to the cessation of chemotherapy needs further investigation. Active immunotherapy with allogeneic AML blasts leads to the appearance of antibody with anti-HL-A specificity in some of the patients' sera (Harris, Wentzel and Freeman, 1975; Hersey et al., 1973; Klouda et al., 1975) though no conclusive evidence has been presented showing that immunotherapy leads to the formation of antibody to autochthonous AML blasts (see review by Harris, 1973 
MATERIALS AND METHODS
Patients and controls.-The patients studied had all beentreated with cytosine arabinoside (Ara-C) and daunorubicin induction chemotherapy. When the patients were judged to be in full remission by bone marrow examination (less than 50 blasts) they received a final course of Ara-C and daunorubicin and commenced immunotherapy one week later. Controls were normal laboratory personnel.
Immunotherapy.-All patients described had received maintenance immunotherapy consisting of weekly injections of 109 viable, washed, x-irradiated (101 rad) allogeneic blasts delivered intradermally/subcutaneously into 3 limbs, and a saline suspension of BCG (Glaxo Laboratories, Greenford), containing approximately 106 live organisms delivered by 20 needle Heaf gun fired twice into the fourth limb Norway) in straight-sided flat-bottomed glass tubes (100 x 14 mm) followed by a centrifugation at 4°C for 40 min at 400 g (Boyum, 1968) . The cells at the interface of the plasma and Ficoll were removed and washed twice in TC 199/HEPES containing 10% FCS, after which they were resuspended in RPMI-1640 containing 1000 heat-inactivated human AB serum.
Mixed cell cultures.-Mixed cultures (4 ml) of patients' or normal leucocytes with AML immunotherapy blasts or with cell lines were initiated in screw-top glass culture tubes (16 x 120 mm, Flow Laboratories, Scotland). The stimulating cells (AML-I or cell lines) were first given a dose of 104 rad x-irradiation from a 137Cs source and cultured with leucocytes (2 x 106/ml) at a ratio of one stimulating cell to 10 responding eells.
After 6 days at 37°C, replicate cultures of each leucocyte and stimulating cell combination were pooled, washed once in TC 199 HEPES and leucocytes adjusted to 1-2x 106/ml.
Cell-mediated cytotoxicity (CMC).-Target cells for the CMC assay were the same cells used to stimulate in the sensitization phase of the test. They were labelled for 1 h with 01 ml of Na251CrO4 (sp. act. 1 mCi/ml Radiochemical Centre, Amersham) per 5 x 106 cells in TC 199/HEPES then washed in a tenfold volume of the same culture medium, re-incubated in 10 vol of this medium for 1 h, further washed and adjusted to 105 cells/ml. For CMC tests, cultured normal or patient leucocytes (0 1 ml) were added to each well in sterile styrene plates with 96 flat-bottomed wells (Cooke Microtitre, M29 ART, Dynatech Laboratories, Billinghurst) so that each target cell was exposed to each leucocyte culture combination, each test being reproduced in quadruplicate wells. The plates were centrifuged at 60 g for 2 min, covered and incubated at 37°C for 4 h. They were then cooled at 4°C, briefly re-spun at 60 g and 01 ml of supernatant medium removed from each well and placed in plastic tubes.
The supernatant was counted for 51Cr in a Wallac DECEM GTL 300-500 Gamma scintillation counter. Percentage CMC was calculated from (E -S/T -S) x 100 where E = 51Cr release in the presence of leucocytes, S = spontaneous 51Cr release by target cells alone and T = total release from target cells alone freeze-thawed x 3. Specific CMC was calculated by subtracting the percentage CMC on target cells in the presence of unstimulated leucocytes from the percentage CMC in the presence of stimulated leucocytes. The significance of 51Cr release from the target cells was calculated by Student's t tests comparing (1) 51Cr release by unstimulated leucocytes with 51Cr release by target cells alone and (2) 51Cr release with stimulated compared with unstimulated leucocytes.
RESULTS
The results of 2 representative experiments comparing leucocytes from patients with normal controls are shown in Table I .
In both experiments, neither unstimulated normal nor patients' leucocytes cultured in vitro for 6 days showed significant cytotoxicity to any (AML-J, BL or LCL) of the target cells. In contrast, leucocytes from the patients receiving AML-I blasts as part of their treatment and re-stimulated in vitro with AML-J blasts showed strong specific cytotoxicity to AML-J blasts and to BL and LCL cells, whereas normal leucocytes cultured with AML-I blasts were not cytotoxic. Stimulation of normal and patient leucocytes were cytotoxic to Raji targets (Experiment 2, normal and patient). However, no cytotoxicity was observed when Rajior MICH-stimulated leucocytes (normal or AML) were tested on AML target cells.
The CMC values in these 2 experiments, and a series of 7 similar experiments in which patients receiving immunotherapy were compared with normal controls, are depicted in Fig. A-D (Fig. A) . However, the specific CMC of patient leucocytes stimulated by AML-I blasts is considerably enhanced compared with normal leucocytes on AML-targets but not on Raji, and less so on MICH targets (Fig. B) . The result of stimulating leucocytes with Raji or MICH cells ( Fig. C and D) did not particularly enhance the CMC by patient compared with normal leucocytes, though both groups showed greater CMC compared with unstimulated leucocytes (Fig. A) , particularly those cultures stimulated with MICH cells and tested against MICH and Raji targets (Fig. D) . The results shown in Table II compare the frequency of significantly positive cytotoxic tests in normals and patients taken from the values depicted in the Figure. The frequency of positive tests using unstimulated normal or patient leucocytes did not greatly differ whereas the frequency of positive tests in which AML-I blast-stimulated leucocytes were cytotoxic to AML-J targets was much higher in patients compared with normals and was higher when these same patients' leucocytes were tested against Raji and MICH cells. In contrast, the frequency 10 of positive cytotoxic reactions using Rajiand MICH-stimulated leucocytes against all 3 target cell types was not markedly different when patients were compared with normals. The HL-A phenotypes of normal and AML patients leucocytes and the stimulating AML blasts were not matched in these experiments, thus differences were present in all cases with respect to the HL-A major histocompatibility complex (Thorsby, 1974) .
DISCUSSION
The CMC test described here is based on observations originally made in the mouse (Haiyry and Defendi, 1970) and confirmed in man (Lightbody and Bach, 1972; Solliday and Bach, 1972 The antigens responsible for reactivation of CMC in the AML patients studied here are not known. Leucocyte stimulation in allogeneic normal mixed leucocyte cultures (MLC) depends upon differences in antigens controlled by the major histocompatibility complex, the so-called leucocyte defined (LD) antigens (Amos and Bach, 1968; Yunis and Amis, 1971; Eijsvoogel et al., 1973) . Leucocyte activation by LD antigens seems to be essential for the development of cytotoxicity to serologically defined (SD) HL-A antigens on the target cells (Eijsvoogel et al., 1973) . Whilst AML-I blasts from different patients often stimulate normal leucocytes in vitro (Taylor et al., unpublished) , it is not clear why such activated normal leucocytes in our experiments generally fail to exhibit cytotoxicity to AML-J blasts as targets since HL-A SD antigens are known to be present on AML blasts (Harris et al., 1975 suggest that cytotoxic leucocytes differentiate to become long-lived memory cells which gradually lose their cytotoxicity but which reappear upon re-exposure to alloantigen. The difference between normal and AML remission leucocytes could be explained in a similar way by regarding the responding cells in the AML-J-stimulated patient leucocyte cultures as memory cytotoxic leucocytes which are unable to mediate CMC without reactivation in vitro.
The cross-reactive cytotoxicity of normal and patient leucocytes on R aji and MICH cells suggests the participation of common stimulating/target antigens. Both cell lines are positive for EpsteinBarr virus nuclear antigen (Taylor, unpublished observations) which could be responsible for determining common cellsurface antigens. The fact that AML-Jstimulated patient leucocytes were also cytotoxic to both cell lines in some tests whilst cell line-stimulated normal and patient leucocytes were cytotoxic to AML-J blasts, suggests the participation of common target HL-A SD antigens in these tests, since AML-J blasts are devoid of the EB virus genome (Taylor, unpublished observations).
The requirements for the successful active immunotherapy of remission AML patients should be the effectiveness of the allogeneic AML-J blasts as primary immunogens and continuous recruitment thereafter of cytotoxic leucocytes from a pool of memory leucocytes. To this end, these studies indicate that immunotherapy is achieving this aim, at least in terms of immunity to allogeneic immunotherapy blasts. However, a more rational basis for the selection of AML-I blasts should be the object of further study since some blasts are known to be nonstimulatory. Whether immunity to AML-I blasts is cross-reactive with autochthonous AML blasts is more open to doubt in view of our failure, so far, to detect cross-reactivity in several experiments with different patients.
